Waft Pharma Private Limited - Due diligence report

A 360° intelligence report on Waft Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals - …

2017-10-26 Rajamahendravaram, Andhra Pradesh Active Unlisted Active Compliant
Share
View plans Plan
WP Waft Pharma Private Limited
View plans Plan
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹349 50% off New user
Or enjoy up to 50% off with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Waft Pharma — 360° Intelligence Report

Generated from MCA filings & public records
67/100
Trust Score
Moderate

Waft Pharma is assessed as Moderate with a Trust Score of 67/100. Waft Pharma is an active private limited indian non-government company incorporated in 2017, operating in the Pharma sector. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 09 Jul 2026 from the latest processed filings. Waft Pharma Private Limited snapshot & full profile →

Financial Health › Weak
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
67/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
75/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
40/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
55/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 2 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.
  • Elevated gearing (D/E 38%).
  • Working-capital cover adequate.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 75/100 Low Risk
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2022 - filings overdue.
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
VENKATA SUBBARAO GIDUGU 01234567 Director 01/04/2018 6 yrs Approved
VENKATA RAMAIAH TUMATI 01234567 Director 01/04/2018 6 yrs Approved
SURYA CHANDRA SEKHARA RAO SAMSANI 01234567 Director 01/04/2018 6 yrs Approved
SAI DILEEP VISWANADHA 01234567 Director 01/04/2018 6 yrs Approved
SANTHI SREE TUMATI 01234567 Director 01/04/2018 6 yrs Approved
  • 5 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2019 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 55 · Distress 55
Growth signals & trust indicators
Asset base grew 1.42 - capacity expansion.
Operating for 8 years.
Active GST registration(s).
Distress signals & risk flags
Losses deepening year-on-year.
Outside liabilities up 2.1x in a year.
Statutory filings appear overdue.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence67/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment49/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view53/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 11 events
30 Sep 2022
Last AGM held
Annual general meeting
31 Mar 2022
Latest balance sheet
Filed with ROC
21 Oct 2020
Director appointed
VENKATA SUBBARAO GIDUGU (Director)
31 Mar 2018
Director appointed
VENKATA RAMAIAH TUMATI (Director)
Director ceased
BALA SADASIVUNI
Director ceased
SUDHAKAR SEETAMRAJU
15 Feb 2018
Securities allotted
10000 Equity Shares Without Differential Rights - 10.00 Lakh raised
26 Oct 2017
Incorporated
Registered with Roc Vijayawada
Director appointed
SURYA CHANDRA SEKHARA RAO SAMSANI (Director)
Director appointed
SAI DILEEP VISWANADHA (Director)
Director appointed
SANTHI SREE TUMATI (Director)
10

Key Observations

Auto-generated from the data above
Debt-to-equity stands at 24% - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
5 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2019 annual return.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Star Life Sciences Private Limited U24230TZ2012PTC018211 Hosur, Tamil Nadu, India
Cryogenex Diagnostics Private Limited U85100JK2010PTC003210 Jammu, Jammu & Kashmir, India
Pace Medical Systems Private Limited U51397KL2005PTC018324 Trivandrum, Kerala, India
Stosswelle Healthcare Private Limited U85100MH2010PTC210496 Mumbai, Maharashtra, India
Cudure Healthcare Private Limited U74900AP2016PTC098180 Vishakapatanam, Andhra Pradesh, India
Bramaveda Ayurveda Hospitals And Organics Private Limited U74999UP2016PTC087019 Ghaziabad, Uttar Pradesh, India
Kumars Cosmetic Clinic Private Limited U93090MH2016PTC287631 Sion East, Maharashtra, India
Wayforward U85100DL2015PTC288230 Delhi, Delhi, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Waft Pharma before audits and certifications: compliance score 75/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Waft Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 55/100, margin trends, ownership structure and peer set for Waft Pharma - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 67/100, distress signals and MSME payment-delay disclosures - know whether Waft Pharma pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Waft Pharma - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Waft Pharma an active company?

Waft Pharma has MCA status “Active” with a compliance score of 75/100 (Low Risk).

Is Waft Pharma financially healthy?

Waft Pharma has a Financial Health Score of 40/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Waft Pharma?

Its overall Trust Score is 67/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Waft Pharma?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 5 active director(s) are on record.

Does Waft Pharma have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Waft Pharma up to date with its ROC filings?

Last balance sheet is for Mar 2022 - filings overdue. Overall compliance score: 75/100 (Low Risk).

Is it risky to lend to Waft Pharma?

Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.